MS PHARMA’s Post

💊🌍 The 2024 #MedSafetyWeek is at this week. This international campaign unites pharmaceutical authorities and organizations worldwide to promote safe medication practices. This year’s theme emphasizes the correct use of medicines to help prevent adverse drug reactions (ADRs). 💡 Why are ADR reports important? These reports, submitted by You, healthcare professionals, consumers, or their representatives, help detect potential new safety signals that may not yet be listed on the medication’s packaging. They provide observations that, after thorough scientific review, contribute to understanding the balance of benefits and risks of a medicine. Visit the campaign site for more details and materials: https://lnkd.in/drV5Gdmu Let’s work together to ensure safe use of medicines 🌟 Oriola is big part of safe use of medicines in Nordics by offering pharmacovigilance and medical information services to pharmaceutical companies. Read more here: https://lnkd.in/dGi7BHki ▪️▪️▪️ 💊 How to report of adverse reactions? Check country specific orders from authorities below: SWEDEN: https://lnkd.in/dMQHBkn5 FINLAND: https://lnkd.in/dgr7R6wx #healthforlife #oriola #getthenordics #adr #fimea #läkemedelsverket

🎉 Big news for Saudi Arabia! The Saudi Food and Drug Authority (SFDA) has become the first regulatory authority in the Middle East to join the Management Committee of the International Council for Harmonization (ICH). The ICH is a global organization that brings together regulatory authorities and pharmaceutical companies to develop unified guidelines for drug safety, quality, and efficacy. It plays a critical role in streamlining drug registration and advancing healthcare standards worldwide. This is a major milestone, putting Saudi Arabia at the forefront of global pharmaceutical regulation and innovation. Congrats to the SFDA for leading the way in shaping the future of healthcare! 🌍💊 #SFDA #ICH #Pharmaceuticals #Healthcare #Saudi_Arabia #MENA

It was my pleasure to speak at the Arab Pharmaceutical Industries Forum titled “Value Added Medicines, the way forward in Arab countries” which was in Amman on July 2&3. Value Added Medicines (VAM) address patients’ unmet needs through repurposing existing medicines. They represent an opportunity to manufacturers to differentiate specially in a highly competitive and protected markets. Collaboration with academia is a key to identify the needs, integrate and deliver solutions & improve heathcare outcomes. Overcoming the barriers including regulatory & pricing issues is essential to incentivise the research & facilitate the availability of VAM. #VAM value added medicines #safety #efficacy

Generic and biosimilar medicines offer comparable safety, quality and efficacy to original reference medicines at often far lower costs. On World Patient Safety Day, STADA supports industry group Medicines for Europe in promoting equitable access to high-quality medicines. As Europe's pharmaceutical legislation is updated, it is vital that we foster timely competition that optimizes patient access to safe, high-quality, effective medicines. A modern digitized regulatory network; support for European medicines manufacturing and more secure supply chains; incentives to invest in off-patent innovation - just some of the initiatives that can empower progress and ensure we leave no patient behind. #CaringForPeoplesHealth #LevellingUp

EMA Pubshlished the variation guidelines Pharmaceutical Strategy for Europe, the Commission is reviewing the current rules governing the procedures for post-authorisation changes to the terms of a marketing authorisation for medicines products for human use, with the purpose to make the lifecycle management of medicines more efficient and future proof and ensuring the protection of public health in the European Union. #regulatoryaffairs #regulatory #regulatorysubmission #cmc #dossier #regulatoryscience #varation #EMA

Naming medicines is no small task! The EMA's video highlights the rigorous standards that ensure medicine names are clear, accurate, and safe for patients—standards we live by every day. At Brandsymbol, we specialize in creating global pharmaceutical names that meet not only regulatory guidelines but also resonate with patients and healthcare professionals worldwide. From avoiding confusion and ensuring cultural relevance to aligning with brand strategy and therapeutic intent, we take a comprehensive approach to name creation. Because a name isn’t just a name—it’s a promise of trust, safety, and innovation. #Brandsymbol #naming #branding

Some of the basic rules can be used also for non medicinal product's name selection.

Collaboration across continents is key, and it's inspiring to see the EMA sharing its expertise to strengthen regulatory frameworks in Africa. Together, we can ensure better healthcare outcomes for all! 🌍 #GlobalHealth #Collaboration #PatientCare

We move closer to a future of healthcare in Africa with the setup of the African Medicines Agency (AMA) As healthcare professional, I eagerly anticipate the positive impacts the AMA will bring, not just for regulatory efficiency, but for patients across Africa. AMA will help bridge gaps in healthcare equity and foster a healthier future for all. #AfricanMedicinesAgency #Healthcare #Innovation #Regulatory #AMMadagascar #MinSanMadagascar #SmeeLifeSciences

The African Medicines Agency (AMA), expected to be fully operational by November 2027, will establish a continent-wide regulatory model to support the growth of Africa’s pharmaceutical industry through alignement and collaboration between national authorities. By aligning with EMA standards, this framework will offer a competitive advantage to European companies entering African markets, while also raising patient safety standards across the continent. This approach facilitates the availability of high-quality medicines and supports industry growth in both Africa and Europe. #pharma #regulatory #harmonization #africa #EU